Transfer of carisoprodol to breast milk.
There is no published information on the transfer of the centrally acting muscle relaxant carisoprodol and its active metabolite meprobamate into breast milk. The objective of this study was to quantify the excretion of carisoprodol and meprobamate in human milk and estimate the dose received by breast-fed infants. The concentrations of carisoprodol and meprobamate were measured in breast milk on 4 consecutive days at steady-state conditions in one woman using carisoprodol 2100 mg/d. The average milk concentrations were 0.9 microg/mL for carisoprodol and 11.6 microg/mL for meprobamate. Based on the milk concentrations measured, the absolute dose ingested by an exclusively breast-fed infant could be estimated at 1.9 mg/kg per day, and the relative dose would be 4.1% of the weight-adjusted maternal dose. No adverse effects were observed in the infant, but the infant was partly fed with formula because of insufficient maternal milk production. Thus, the authors consider that at least during prolonged use, lactation is generally inadvisable until more clinical data are available.
Nordeng
H
H
Department of Pharmacotherapeutics, University of Oslo, Oslo, Norway. h.m.e.nordeng@farmasi.uio.no
Zahlsen
K
K
Spigset
O
O
D000328:Adult; D001692:Biological Transport; D002328:Carisoprodol / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008620:Meprobamate / Q000493:pharmacokinetics; D008895:Milk, Human / Q000378:metabolism*; D009125:Muscle Relaxants, Central / Q000493:pharmacokinetics*
D009125:Muscle Relaxants, Central; D002328:Carisoprodol; D008620:Meprobamate